WCAI (Cape and Islands NPR) – Advances in Alzheimer's Diagnosis, but Where are the New Drug Therapies?
Last month, federal government decided that it will not pay to scan suspected Alzheimer's patients, unless the scan is being used to see if someone is a good candidate to participate in a drug trial. Samuel Gandy, MD, Professor of Neurology and Psychiatry, and Associate Director of the Mount Sinai Alzheimer's Disease Research Center at the Icahn School of Medicine at Mount Sinai, said wider use would give researchers more information about the disease, and there's value, he said, in affirming the diagnosis people get in their doctor's office. "These things," he said, "have an educational value for the public who still see diseases like Alzheimer's as mysterious, and perhaps the public would be more supportive if they understood what we're doing - that now we have a scan, we can see the disease, and now we are developing drugs to treat it."
-Dr. Sam Gandy, Professor, Neurology, Psychiatry, Associate Director of the Mount Sinai Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai